BRIM

Technology helps ID aggressive early breast cancer

When a woman is diagnosed with the earliest stage of breast cancer, how aggressive should her treatment be? Will the non-invasive cancer become invasive? Or is it a slow-growing variety that will likely never be harmful? Researchers at the University of Michigan developed a new technology that can identify aggressive forms of ductal carcinoma in situ, or stage 0 breast cancer, from non-aggressive varieties. The technique combines imaging and mathematics. It’s called biomarker ratio imaging microscopy, or BRIM.

DCIS sample shows aggressive biomarker at high contrast
DCIS sample shows aggressive biomarker at high contrast
Source: University of Michigan Health System

“A patient with DCIS is typically treated as if she has invasive disease, which is easy to understand. When women hear breast cancer, they’re petrified. And physicians are keenly concerned about outcomes as well,” says study author Howard R. Petty, Ph.D., professor of ophthalmology and visual sciences and of microbiology and immunology. “But, DCIS is not the same disease for everyone. If we can identify potentially non-aggressive lesions, perhaps those women don’t need aggressive treatment.”

BRIM combines traditional pathology techniques and fuses it with mathematical analysis to determine the relative levels of certain biomarkers in a tumor. Petty and co-author Andrea J. Clark looked at biopsy samples from 23 patients with DCIS. They used fluorescence imaging, in which tumors are stained to identify key biomarkers. Each biomarker was stained a different color. The stained samples were then entered into a computer program that determines the ratio of biomarker in each pixel.

Some biomarkers are highly expressed in cancer; others have very low expression. With BRIM, researchers take the ratio of expression. This means high and low do not cancel each other out, but rather combine to form an image of improved contrast. Using this technique, researchers could separate the DCIS patient samples into those with a lot of cancer stem cells – which are highly aggressive – and those that resembled benign tumors. They found 22 percent of the samples had low scores suggestive of very slow-growing, non-aggressive disease. “This approach is going to be a new and powerful one. It works because we’re looking at it mathematically,” Petty says. The results are published in the Nature journal Scientific Reports.

Ratio imaging microscopy was used in the 1990s to look at calcium signals. Here, the researchers resurrected this technique and applied it using antibodies and biomarkers. Biomarkers were selected based on an extensive literature search. The researchers suggest that another advantage to BRIM is that it combines multiple biomarkers, rather than relying on a single marker.

Rates of ductal carcinoma in situ have increased since screening mammography became common. Some experts believe that DCIS can become invasive breast cancer, but this has not been proven. Currently, there is not a way to stratify the disease based on aggressiveness. The researchers suggest that in addition to preventing overtreatment, BRIM could be used to help more broadly with breast cancer treatment decisions. As the biomarker literature becomes more expansive in other cancer types, the researchers say they will expand their work to other forms of cancer.


Source: University of Michigan Health System

13.07.2016

Read all latest stories

Related articles

Photo

Researchers grow cardiac tissue on “spider silk” substrate

Genetically engineered fibers of the protein spidroin, which is the construction material for spider webs, has proven to be a perfect substrate for cultivating heart tissue cells, MIPT researchers…

Photo

ECCMID 2015

Curetis launches next-generation pneumonia application

Curetis AG, a developer of next-level molecular diagnostic solutions, announced the successful completion of the clinical and analytical CE performance evaluation of its next-generation Unyvero P55…

Euromedlab 2009

"In-vitro veritas", the slogan of the 18th European Congress of Clinical Chemistry and Laboratory Medicine, which took place in June, underlined the significance of in vitro diagnostics for…

Related products

BD Vacutainer Urine Tubes for Microbiology

Other

BD Vacutainer Urine Tubes for Microbiology

BD – Becton Dickinson
Hund – medicus plus Myko

Microscopy

Hund – medicus plus Myko

Helmut Hund GmbH
Olympus – CX33

Microscopy

Olympus – CX33

Olympus Europa SE & Co. KG
Sysmex - UF-5000

Identification/Susceptibility

Sysmex - UF-5000

Sysmex Europe GmbH
Atlas Genetics - Atlas Genetics io system

Infectious diseases testing

Atlas Genetics - Atlas Genetics io system

Atlas Genetics Ltd
DiaSys Diagnostic Systems - InnovaStar

Clinical chemistry

DiaSys Diagnostic Systems - InnovaStar

DiaSys Diagnostic Systems GmbH